Sagent Pharmaceuticals Announces Launch of Atracurium Besylate Injection

Sagent Pharmaceuticals, Inc.

today announced the launch of Atracurium Besylate Injection, USP, the generic form of the neuromuscular blocker Tracrium®, in 50 mg per 5 mL latex-free vials. According to IMS data for the twelve-months ended March 2012, the U.S. market for Atracurium approximated $2.4 million. As with all products in Sagent's portfolio, Atracurium features the company's PreventIV Measures^SM packaging and labeling designed to aid in the reduction of medication errors.